Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma.

MLA

Santo, Loredana, et al. “Preclinical Activity, Pharmacodynamic, and Pharmacokinetic Properties of a Selective HDAC6 Inhibitor, ACY-1215, in Combination with Bortezomib in Multiple Myeloma.” Blood, vol. 119, no. 11, Mar. 2012, pp. 2579–89. EBSCOhost, https://doi.org/10.1182/blood-2011-10-387365.

APA

Santo, L., Hideshima, T., Kung, A. L., Jen-Chieh Tseng, Tamang, D., Min Yang, Jarpe, M., van Duzer, J. H., Mazitschek, R., Ogier, W. C., Cirstea, D., Rodig, S., Eda, H., Scullen, T., Canavese, M., Bradner, J., Anderson, K. C., Jones, S. S., & Raje, N. (2012). Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. Blood, 119(11), 2579–2589. https://doi.org/10.1182/blood-2011-10-387365

Chicago

Santo, Loredana, Teru Hideshima, Andrew L. Kung, Jen-Chieh Tseng, David Tamang, Min Yang, Matthew Jarpe, et al. 2012. “Preclinical Activity, Pharmacodynamic, and Pharmacokinetic Properties of a Selective HDAC6 Inhibitor, ACY-1215, in Combination with Bortezomib in Multiple Myeloma.” Blood 119 (11): 2579–89. doi:10.1182/blood-2011-10-387365.